Navigation Links
CureFAKtor Pharmaceuticals to Present at 10th Annual BIO Investor Forum
Date:10/19/2011

BUFFALO, N.Y., Oct. 19, 2011 /PRNewswire/ -- CureFAKtor Pharmaceuticals, LLC, a privately-held biopharmaceutical company focused on the research and development of Focal Adhesion Kinase (FAK) inhibitors for cancer, announced today that H. Shep Wild, President and Chief Executive Officer, will present a company overview at the Biotechnology Industry Organization's 10th Annual BIO Investor Forum in San Francisco, CA on Wednesday, October 26 at 9:00 am.

The BIO Investor Forum features presentations by leading private and emerging public biotechnology companies to healthcare venture and private equity investors, buy-side and sell-side investment companies and biopharmaceutical and industry business development and licensing executives.

CureFAKtor's proprietary FAK technology platform may represent a significant breakthrough in the treatment of most solid tumors in that its unique mechanism of action disrupts the signaling of FAK in tumors by targeting specific protein to protein bindings.  CureFAKtor scientists first discovered FAK in human tumors approximately 20 years ago.  FAK is much like a force field that cocoons cancer cells and allows them to survive the effects of chemotherapy, radiation and other natural processes designed to execute aberrant cancer cells.  Since FAK is over-expressed in virtually all solid tumors, the technology has broad applicability in oncology.

More than 40 compounds have been identified that target FAK signaling sites.  In preclinical studies, lead small molecule oral compound CFAK-C4 demonstrated efficacy in a number of cancers including pancreatic, breast, advanced melanoma and neuroblastoma. The Company's second product candidate, CFAK-Y15 is being investigated for the treatment of breast, pancreatic, neuroblastoma and colon cancer. The Company has promising results with CFAK-Y15 in lung cancer and glioblastoma.

CureFAKtor received Orphan Drug Designation by the U
'/>"/>

SOURCE CureFAKtor Pharmaceuticals, LLC
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. CureFAKtor Pharmaceuticals Receives Orphan Drug Designation for Its Lead Compound CFAK-C4 for the Treatment of Pancreatic Cancer
2. CureFAKtor Pharmaceuticals Demonstrates that Novel Focal Adhesion Kinase (FAK) Inhibitors Targeted to Protein-Protein Binding Sites Inhibit Pancreatic Cancer Cells Growth
3. CureFAKtor Pharmaceuticals Demonstrates that Novel Focal Adhesion Kinase (FAK) Inhibitors Decrease Pancreatic Cancer Tumor Blood Flow and Reduce Blood Vessel Density
4. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
7. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
8. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
9. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
10. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
11. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... SAN DIEGO , Dec. 17, 2014 ... PHIA) and Volcano Corporation (NASDAQ: VOLC ), a ... applications, today announced that they have entered into a definitive ... tender offer to acquire all of the issued and outstanding ... total equity purchase price of USD 1 billion (approx. EUR ...
(Date:12/17/2014)... HOLBROOK, N.Y. , Dec. 17, 2014 /PRNewswire/ ... that The Depository Trust Company (DTC) has made ... the Deposit Chill on the Company,s stock effective ... of Northstar,s common stock for depository and book ... and the Company is now once again fully ...
(Date:12/17/2014)... 17, 2014  ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE ... Trademark Office (USPTO) has issued a key patent ... immunotherapeutic vaccine targeting six tumor antigens that are ... Patent No. 8,871,211, which issued October 28, 2014, ... a dendritic cell composition comprising peptide epitopes of ...
Breaking Medicine Technology:Philips to acquire Volcano to expand global leadership position in image-guided therapy market 2Philips to acquire Volcano to expand global leadership position in image-guided therapy market 3Philips to acquire Volcano to expand global leadership position in image-guided therapy market 4Philips to acquire Volcano to expand global leadership position in image-guided therapy market 5Philips to acquire Volcano to expand global leadership position in image-guided therapy market 6Philips to acquire Volcano to expand global leadership position in image-guided therapy market 7Philips to acquire Volcano to expand global leadership position in image-guided therapy market 8Northstar announces that the DTC chill on MDIN has been officially lifted 2Northstar announces that the DTC chill on MDIN has been officially lifted 3ImmunoCellular Therapeutics Announces Issuance of Key Patent For ICT-107 Cancer Vaccine 2
... Jan. 22 Protalix,BioTherapeutics, Inc. (Amex: PLX ... concept results in an animal study conducted as ... is being conducted under the agreement the Company ... the technology transfer,arm of the Hebrew University of ...
... approved to reduce both A1C and LDL cholesterol, ... Inc.,announced that the United States Food and Drug ... glycemic control,(measured as hemoglobin A1C) in adults with ... or insulin, either alone or in,combination with other ...
Cached Medicine Technology:Protalix BioTherapeutics Extends Research Agreement With Yissum Based on Promising Acetylcholinesterase Program Results in Animal Study 2Protalix BioTherapeutics Extends Research Agreement With Yissum Based on Promising Acetylcholinesterase Program Results in Animal Study 3Photo: Welchol(TM) (colesevelam HCl) Receives FDA Approval to Reduce Blood Glucose in Adults with Type 2 Diabetes 2Photo: Welchol(TM) (colesevelam HCl) Receives FDA Approval to Reduce Blood Glucose in Adults with Type 2 Diabetes 3Photo: Welchol(TM) (colesevelam HCl) Receives FDA Approval to Reduce Blood Glucose in Adults with Type 2 Diabetes 4Photo: Welchol(TM) (colesevelam HCl) Receives FDA Approval to Reduce Blood Glucose in Adults with Type 2 Diabetes 5Photo: Welchol(TM) (colesevelam HCl) Receives FDA Approval to Reduce Blood Glucose in Adults with Type 2 Diabetes 6Photo: Welchol(TM) (colesevelam HCl) Receives FDA Approval to Reduce Blood Glucose in Adults with Type 2 Diabetes 7
(Date:12/21/2014)... The Oncology Institute of Hope and Innovation hosted their third ... The Hope for the Holidays Toy Drive is a way ... during the holiday season. This year, the toy drive was ... offices. This event continues to be successful year after year. ... managers and assistant managers came out and not only donated ...
(Date:12/20/2014)... 21, 2014 BambooIndustry.com is a professional ... . The business has recently shown its new engineered ... all its bamboo flooring models. , BambooIndustry.com’s customers come ... Asia and more. According to the CEO of the ... very fast in the past few years, and the ...
(Date:12/20/2014)... MissyDress, a distinguished special dress supplier, has just ... has drastically cut prices to all its prom dresses ... 30, 2015. Many of the hottest styles are sold ... dresses, and more. , A spokesman for MissyDress says, ... A-line princess prom dresses or sweetheart chiffon prom dresses, ...
(Date:12/20/2014)... An improving macroeconomic landscape and a ... Massage Services industry over the five years ... the anticipated 1.0% annualized increase in per capita disposable ... the means to afford additional massages. “While the share ... a given year has declined from 2009 to 2012, ...
(Date:12/20/2014)... 2014 DePuy Pinnacle hip lawsuits ... of the artificial hip system was defectively designed ... courts, Bernstein Liebhard LLP reports. According to an ... Court on December 2nd, counsel in 10 DePuy ... plaintiffs on November 19, 2014, with depositions to ...
Breaking Medicine News(10 mins):Health News:BammbooIndustry.com: Big Discounts On All Kinds Of Bamboo Flooring Collections 2Health News:MissyDress: The Prices of Prom Dresses Just Reduced 2Health News:Massage Services in the US Industry Market Research Report from IBISWorld Has Been Updated 2Health News:Massage Services in the US Industry Market Research Report from IBISWorld Has Been Updated 3Health News:New Jersey Court Overseeing DePuy Pinnacle Hip Lawsuits Issues New Order, Bernstein Liebhard LLP Reports 2Health News:New Jersey Court Overseeing DePuy Pinnacle Hip Lawsuits Issues New Order, Bernstein Liebhard LLP Reports 3Health News:New Jersey Court Overseeing DePuy Pinnacle Hip Lawsuits Issues New Order, Bernstein Liebhard LLP Reports 4
... new center to produce and sell human stem cells; ... the first ever in Europe,// envisaged to give an ... research. The Roslin Cells Center is a brain child ... Enterprise, Edinburgh University and the Scottish National Blood Transfusion ...
... A recent study reveals that islet cell transplantation may decrease ... diabetes. // ,This study conducted by James Shapiro, ... and his team was published in Thursday's New England Journal ... from dead donors were transplanted into 36 patients affected by ...
... Information on the Disease Control Priorities project that plans ... countries // was given to health ministers from the ... ,According to the Pan American Health Organization, ... of the "best buys" in health improvement in developing ...
... announced that it is adequately geared with a ... // control measures, to counter a potential chikungunya ... Ernakulum and Kozhikode have reported the chikungunya fever. ... the Health watch dogs, Ms. Sreemathy, Health Minister, ...
... of Radiology says that a mathematical formula can predict ... percent accuracy.// Researchers say this will allow doctors to ... of women have different levels of bone mineral density ... as to how physicians should assess their future fracture ...
... At the turn of the 20th century, tobacco baron James ... figure of 430 million, jabbed his finger at a map ... to sell cigarettes." ,One hundred years on, Duke's prophesy ... population has since grown to 1.3 billion, has been realised ...
Cached Medicine News:Health News:Formula Predicts Osteoporotic Fracture Risk 2Health News:World's 3 out of 10 Cigarettes Smoked in China 2
The 40D is ideal for pediatric ophthalmoscopy and other examinations requiring expansive fundus visibility. Alternatively, this lens may be used at the slit lamp biomicroscope to provide an extremely...
This excellent mid-power lens provides medium field and magnification, with an ideal diameter for grip andmanipulation in the orbital area....
The 15D provides high magnification along with an optimized working distance from the cornea. With its 4.11x magnification it is also well suited for disc and macular observation....
The Professional ophthalmoscope has been designed to ensure ultimate control. Lenses, graticules and filters can all be introduced at the touch of a fingertip without the need to pull away from the p...
Medicine Products: